相关临床试验
88
16 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
3.4%
已完成
17
19.3%
尚未招募
13
14.8%
招募中
22
25.0%
Unknown
33
37.5%
暂无批准数据
- A multicenter Chinese study of 158 Crohn's disease patients demonstrated that therapeutic drug monitoring (TDM)-guided ustekinumab optimization achieved significantly higher clinical remission rates at 2 years compared to standard therapy (71.3% vs 46.5%). - Patients receiving TDM-guided treatment maintained ustekinumab trough levels ≥3.0 μg/mL through weight-based intravenous reinduction when levels dropped below this threshold, resulting in superior treatment retention rates of 86.2% versus 49.3%. - The optimization strategy proved effective even in patients with baseline endoscopic response or mucosal healing, significantly reducing disease relapse rates over the 2-year follow-up period. - Both ustekinumab and vedolizumab demonstrated safety and efficacy for Crohn's disease of the pouch in a separate multicenter study, with ustekinumab showing superior treatment durability and clinical response rates.
- Global rheumatoid arthritis incidence increased 13.2% from 1990 to 2021, affecting 17.9 million people worldwide by 2021, with significant regional disparities and a shift toward younger age groups. - Despite rising incidence, RA-related mortality dropped by 32.7% over the study period, from 0.09 to 0.06 per 100,000 people, attributed to improved diagnostic capabilities and treatment advances. - Women face disproportionately higher disease burden than men, with mortality rates of 0.08 versus 0.04 per 100,000 people and significantly higher disability-adjusted life years. - AI-driven forecasting models predict continued global RA burden growth through 2040, particularly in low- and middle-income countries, highlighting urgent need for targeted public health interventions.
